Corona Remedies IPO
Bookbuilding IPO | ₹655.37 Cr | Listing at BSE, NSE
IPO Open
Mon, Dec 08, 2025
IPO Close
Wed, Dec 10, 2025
Price Band
₹1,008.00 to ₹1,062.00
Market Cap (Pre-IPO)
₹6,495.20 Cr
IPO Details
| IPO Date | Dec 08, 2025 to Dec 10, 2025 |
| Listing Date | Dec 15, 2025 |
| Face Value | ₹10.00 per share |
| Price Band | ₹1,008.00 to ₹1,062.00 |
| Lot Size | 14 Shares (Minimum: ₹14,868.00) |
| Sale Type | Offer For Sale |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Issue Size | ₹655.37 Crores |
| Total Shares Offered | 6,174,051 shares |
| Fresh Issue | 61,160,088 shares |
| Offer For Sale | 61,160,088 shares |
Subscription Data
| Category | Times Subscribed |
|---|---|
| QIB | 293.80x |
| NII | 634.05x |
| RII | 30.39x |
| Total | 144.54x |
Corona Remedies IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | 30,58,007 (49.53%) |
| Retail Shares Offered | 21,40,606 (34.67%) |
| NII Shares Offered | 9,17,403 (14.86%) |
Corona Remedies IPO Lot Size
Investors can bid for a minimum of 14 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 14 | ₹14,868 |
| Retail (Max) | 13 | 182 | ₹193,284 |
| S-HNI (Min) | 14 | 196 | ₹208,152 |
| S-HNI (Max) | 67 | 938 | ₹996,156 |
| B-HNI (Min) | 68 | 952 | ₹1,011,024 |
Corona Remedies Financial Information (Restated Consolidated)
Corona Remedies Ltd.'s revenue increased by 18% and profit after tax (PAT) rose by 65% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 30 Jun 2025 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 1,012.38 | 929.86 | 830.58 | 595.02 |
| Total Income | 348.56 | 1,202.35 | 1,020.93 | 891.10 |
| Profit After Tax | 46.20 | 149.43 | 90.50 | 84.93 |
| EBITDA | 71.80 | 245.91 | 161.19 | 135.03 |
| NET Worth | 607.02 | 606.34 | 480.41 | 408.52 |
| Reserves and Surplus | 545.86 | 545.18 | 419.25 | 347.36 |
| Total Borrowing | 106.65 | 62.70 | 134.14 | 2.33 |
Amount in ₹ Cr
Key Performance Indicators
As of Monday, March 31, 2025| KPI | Values |
|---|---|
| ROE (Return on Equity) | 27.50% |
| ROCE (Return on Capital Employed) | 41.32% |
| Debt/Equity | 0.10 |
| RoNW (Return on Net Worth) | 24.65% |
| PAT Margin (Profit After Tax Margin) | 12.49% |
| EBITDA Margin | 20.55% |
| Price to Book Value | 10.71 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 24.43 | 30.21 |
| P/E (x) | 43.47 | 35.15 |
| Promoter Holding | 72.50% | 69.00% |
Company Promoters
- The company's promoters are Dr. Kirtikumar Laxmidas Mehta
- Niravkumar Kirtikumar Mehta and Ankur Kirtikumar Mehta.
Company Overview
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.
As of June 30, 2025, the company's diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory).
The company has a pan-India marketing and distribution network with 2,671 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.
The company has two manufacturing facilities, located in the states of Gujarat with an aggregate installed capacity for formulations of 1,285.44 million units per annum.
Company Strengths
- Second fastest growing company in the top 30 Indian pharmaceutical companies by domestic sales from MAT June 2022 to MAT June 2025, well-positioned to seize opportunities in the Indian market.
- Demonstrated capabilities of building a diversified portfolio, including “engine” brands, in our targeted therapy areas.
- Pan-India sales network and marketing strategy focused on the “middle of the pyramid” target market.
- Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities driving a portfolio of differentiated pharmaceutical products.
- Qualified, experienced and entrepreneurial management team supported by marquee investors.
Corona Remedies IPO Peer Comparison
Corona Remedies peer comparison with similar listed entities. (As on March 31, 2025)| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Corona Remidies Limited | 24.43 | 24.43 | 99.14 | - | 24.65 | - | Consolidated |
| Abbott India Ltd. | 665.62 | 665.62 | 1,992.14 | 45.17 | 33.41 | - | Consolidated |
| Alkem Laboratories Ltd | 181.11 | 181.11 | 1,002.37 | 31.39 | 18.07 | - | Consolidated |
| Eris Lifesciences Ltd | 25.85 | 25.81 | 209.73 | 61.81 | 12.21 | - | Consolidated |
| Glaxosmithkline Pharmaceuticals Ltd. | 54.76 | 54.76 | 115.19 | 46.87 | 47.54 | - | Consolidated |
| J.b.chemicals & Pharmaceuticals Ltd. | 42.45 | 41.56 | 220.88 | 42.60 | 19.21 | - | Consolidated |
| Mankind Pharma Limited | 49.28 | 49.20 | 352.51 | 45.77 | 13.89 | - | Consolidated |
| Pfizer Ltd. | 167.79 | 167.79 | 921.88 | 29.63 | 18.20 | - | Standalone |
| Sanofi India Ltd. | 179.46 | 179.46 | 373.68 | 24.47 | 48.05 | - | Standalone |
| Torrent Pharmaceuticals Ltd. | 56.47 | 56.47 | 224.28 | 65.91 | 25.18 | - | Consolidated |
Quick Info
| Sector | Corona Remedies IPO Details |
| Exchange | BSE, NSE |
| Market Cap (Pre-IPO) | ₹6,495.20 Cr |
Important Dates
| IPO Open | Dec 08, 2025 |
| IPO Close | Dec 10, 2025 |
| Allotment Date | Dec 11, 2025 |
| Basis of Allotment | Dec 11, 2025 |
| Credit to Demat | Dec 12, 2025 |
| Listing Date | Dec 15, 2025 |
Lead Manager(s)
JM Financial Ltd.
Registrar
Bigshare Services Pvt.Ltd.
+91-22-6263 8200
Description
- Corona Remedies IPO is a book build issue of ₹655.37 crores. The issue is entirely an offer for sale of 0.62 crore shares of ₹655.37 crore.
- Corona Remedies IPO bidding started from Dec 8, 2025 and ended on Dec 10, 2025. The allotment for Corona Remedies IPO was finalized on Dec 11, 2025. The shares got listed on BSE, NSE on Dec 15, 2025.
- Corona Remedies IPO price band is set at ₹1062.00 per share . The lot size for an application is 14. The minimum amount of investment required by an retail is ₹14,868 (14 shares) (based on upper price). The lot size investment for sNII is 14 lots (196 shares), amounting to ₹2,08,152, and for bNII, it is 68 lots (952 shares), amounting to ₹10,11,024.
- The issue includes a reservation of up to 58,035 shares for employees offered at a discount of ₹54.00 to the issue price.